Skillsoft Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Skillsoft Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jan 31, 2022 | $427.75M | Apr 18, 2022 |
| FY2022 | Jun 11, 2021 | $139.64M | Apr 18, 2022 |
| FY2022 | Jan 31, 2021 | $108.77M | Apr 18, 2022 |
| FY2022 | Aug 27, 2020 | $273.85M | Apr 18, 2022 |
| FY2022 | Jan 31, 2020 | $514.02M | Apr 18, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $512.67M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $530.99M | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | $553.24M | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | $555.12M | Apr 14, 2025 |
| FY2022 | Jan 31, 2022 | $166.18M | Apr 18, 2022 |
| FY2022 | Oct 31, 2021 | $170.56M | Apr 18, 2022 |
| FY2022 | Jul 31, 2021 | $91.01M | Apr 18, 2022 |
| FY2024 | Jun 11, 2021 | $102.49M | Apr 15, 2024 |
| FY2023 | Jan 31, 2021 | $73.25M | Apr 14, 2023 |
| FY2023 | Aug 27, 2020 | $197.67M | Apr 14, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($139.82M) | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | ($121.91M) | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | ($349.29M) | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | ($724.96M) | Apr 14, 2025 |
| FY2022 | Jan 31, 2022 | $7.90M | Apr 18, 2022 |
| FY2022 | Oct 31, 2021 | ($42.86M) | Apr 18, 2022 |
| FY2022 | Jul 31, 2021 | ($11.85M) | Apr 18, 2022 |
| FY2024 | Jun 11, 2021 | ($49.26M) | Apr 15, 2024 |
| FY2023 | Jan 31, 2021 | ($93.72M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2020 | ($72.46M) | Oct 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($89.49M) | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | ($69.62M) | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | ($308.61M) | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | ($804.12M) | Apr 14, 2025 |
| FY2022 | Jan 31, 2022 | ($22.40M) | Apr 18, 2022 |
| FY2022 | Oct 31, 2021 | ($4.36M) | Apr 18, 2022 |
| FY2022 | Jul 31, 2021 | ($16.51M) | Apr 18, 2022 |
| FY2024 | Jun 11, 2021 | ($37.99M) | Apr 15, 2024 |
| FY2023 | Jan 31, 2021 | ($87.94M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2020 | ($906.9K) | Oct 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $55.63M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $60.76M | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | $68.03M | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | $69.80M | Apr 14, 2025 |
| FY2022 | Jan 31, 2022 | $20.37M | Apr 18, 2022 |
| FY2022 | Oct 31, 2021 | $16.44M | Apr 18, 2022 |
| FY2022 | Jul 31, 2021 | $9.88M | Apr 18, 2022 |
| FY2024 | Jun 11, 2021 | $15.01M | Apr 15, 2024 |
| FY2023 | Jan 31, 2021 | $19.28M | Apr 14, 2023 |
| FY2023 | Aug 27, 2020 | $22.96M | Apr 14, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $25.05M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $29.97M | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | $2.82M | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | ($20.93M) | Apr 14, 2025 |
| FY2024 | Jan 31, 2022 | $28.22M | Apr 15, 2024 |
| FY2024 | Jun 11, 2021 | $33.81M | Apr 15, 2024 |
| FY2023 | Jan 31, 2021 | $8.18M | Apr 14, 2023 |
| FY2020 | Dec 31, 2020 | ($720.7K) | Oct 24, 2022 |
| FY2023 | Aug 27, 2020 | $3.92M | Apr 14, 2023 |
| FY2022 | Jan 31, 2020 | ($37.41M) | Apr 18, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.77M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $1.60M | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | $4.18M | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | $4.91M | Apr 14, 2025 |
| FY2024 | Jan 31, 2022 | $6.29M | Apr 15, 2024 |
| FY2024 | Jun 11, 2021 | $641.0K | Apr 15, 2024 |
| FY2023 | Jan 31, 2021 | $2.33M | Apr 14, 2023 |
| FY2023 | Aug 27, 2020 | $3.11M | Apr 14, 2023 |
| FY2022 | Jan 31, 2020 | $10.35M | Apr 18, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $963.12M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $1.11B | Apr 7, 2026 |
| FY2025 | Jan 31, 2024 | $1.27B | Apr 14, 2025 |
| FY2024 | Jan 31, 2023 | $1.64B | Apr 15, 2024 |
| FY2023 | Jan 31, 2022 | $2.22B | Apr 14, 2023 |
| FY2022 | Jan 31, 2021 | $1.55B | Apr 18, 2022 |
| FY2020 | Dec 31, 2020 | $700.93M | Oct 24, 2022 |
| FY2023 | Aug 27, 2020 | $1.50B | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $697.84M | Oct 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $153.55M | Oct 24, 2022 |
| FY2022 | Aug 27, 2020 | $836.76M | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | $78.00M | Oct 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($30.23M) | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $93.85M | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | $205.59M | Apr 7, 2026 |
| FY2026 | Jan 31, 2023 | $531.76M | Apr 7, 2026 |
| FY2025 | Jan 31, 2022 | $1.06B | Apr 14, 2025 |
| FY2024 | Jun 11, 2021 | $105.03M | Apr 15, 2024 |
| FY2024 | Jan 31, 2021 | $579.97M | Apr 15, 2024 |
| FY2020 | Dec 31, 2020 | ($149.12M) | Oct 24, 2022 |
| FY2023 | Aug 27, 2020 | $666.97M | Apr 14, 2023 |
| FY2023 | Jan 31, 2020 | ($2.76B) | Apr 14, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $296.30M | Apr 7, 2026 |
| FY2026 | Feb 1, 2025 | $317.07M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $317.07M | Apr 7, 2026 |
| FY2026 | Feb 1, 2024 | $317.07M | Apr 7, 2026 |
| FY2025 | Jan 31, 2024 | $317.07M | Apr 14, 2025 |
| FY2025 | Jan 31, 2023 | $457.74M | Apr 14, 2025 |
| FY2024 | Jan 31, 2022 | $795.81M | Apr 15, 2024 |
| FY2023 | Jun 11, 2021 | $491.52M | Apr 14, 2023 |
| FY2023 | Jan 31, 2021 | $491.65M | Apr 14, 2023 |
| FY2023 | Aug 27, 2020 | $495.14M | Apr 14, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($1.58B) | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | ($1.44B) | Apr 7, 2026 |
| FY2025 | Jan 31, 2024 | ($1.32B) | Apr 14, 2025 |
| FY2024 | Jan 31, 2023 | ($972.19M) | Apr 15, 2024 |
| FY2023 | Jan 31, 2022 | ($247.23M) | Apr 14, 2023 |
| FY2022 | Jan 31, 2021 | ($93.72M) | Apr 18, 2022 |
| FY2020 | Dec 31, 2020 | ($149.12M) | Oct 24, 2022 |
| FY2023 | Aug 27, 2020 | $0 | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($75.09M) | Oct 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $100.82M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | $100.77M | Apr 7, 2026 |
| FY2025 | Jan 31, 2024 | $136.31M | Apr 14, 2025 |
| FY2024 | Jan 31, 2023 | $170.36M | Apr 15, 2024 |
| FY2023 | Jan 31, 2022 | $138.18M | Apr 14, 2023 |
| FY2022 | Jun 11, 2021 | $117.30M | Apr 18, 2022 |
| FY2022 | Jan 31, 2021 | $71.48M | Apr 18, 2022 |
| FY2023 | Aug 27, 2020 | $92.01M | Apr 14, 2023 |
| FY2022 | Jan 31, 2020 | $18.80M | Apr 18, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $570.77M | Apr 7, 2026 |
| FY2025 | Jan 31, 2025 | $573.27M | Apr 14, 2025 |
| FY2024 | Jan 31, 2024 | $577.49M | Apr 15, 2024 |
| FY2023 | Jan 31, 2023 | $581.82M | Apr 14, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | (16) | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | (14) | Apr 7, 2026 |
| FY2026 | Jan 31, 2024 | (43) | Apr 7, 2026 |
| FY2025 | Jan 31, 2023 | (91) | Apr 14, 2025 |
| FY2022 | Jan 31, 2022 | 0 | Apr 18, 2022 |
| FY2022 | Oct 31, 2021 | 0 | Apr 18, 2022 |
| FY2022 | Jul 31, 2021 | 0 | Apr 18, 2022 |
| FY2020 | Dec 31, 2020 | 0 | Oct 24, 2022 |
| FY2023 | Aug 27, 2020 | 27,612 | Apr 14, 2023 |
| FY2022 | Jan 31, 2020 | (8,483) | Apr 18, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jan 31, 2022 | 0 | Apr 18, 2022 |
| FY2022 | Oct 31, 2021 | 0 | Apr 18, 2022 |
| FY2022 | Jul 31, 2021 | 0 | Apr 18, 2022 |
| FY2020 | Dec 31, 2020 | 0 | Oct 24, 2022 |
| FY2022 | Aug 27, 2020 | 27,612 | Apr 18, 2022 |
| FY2022 | Jan 31, 2020 | (8,483) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Oct 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 8.80M | Apr 7, 2026 |
| FY2026 | Jan 31, 2025 | 8.32M | Apr 7, 2026 |
| FY2025 | Jan 31, 2024 | 8.08M | Apr 14, 2025 |
| FY2024 | Jan 31, 2023 | 8.18M | Apr 15, 2024 |
| FY2023 | Jan 31, 2022 | 133.26M | Apr 14, 2023 |
| FY2023 | Jan 31, 2021 | 4.00M | Apr 14, 2023 |